What Loper Bright Actually Changed for Federal Healthcare Enforcement

For forty years, administrative agencies held an almost insurmountable advantage in federal courts. Under the doctrine of Chevron deference, when a statute governing healthcare program requirements was ambiguous, courts were required to defer to the agency's interpretation—so long as it was "reasonable." On June 28, 2024, the Supreme Court’s decision in Loper Bright Enterprises v. Raimondo dismantled this system, changing the balance of power in federal healthcare enforcement.

For healthcare providers, medical executives, and legal counsel defending against Medicare fraud or regulatory compliance actions, the post-Chevron era represents a fundamental change in the judicial landscape. Sub-regulatory guidance, OIG Special Advisory Bulletins, and CMS local coverage determinations (LCDs) are no longer insulated from judicial review. Challenging an aggressive enforcement theory now starts on a level playing field.

1. The End of Chevron Deference: A Judicial Reset

Under Chevron, if the Department of Health and Human Services (HHS) interpreted an ambiguous Medicare billing rule to support a fraud allegation, federal courts generally accepted that interpretation. This gave CMS and the Office of Inspector General (OIG) de facto lawmaking power, allowing them to expand the scope of criminal and civil liability through administrative rule-making.

The Loper Bright ruling re-established that Article III courts, not executive agencies, hold the sole power to interpret statutes. Judges must now exercise independent judgment when determining whether an agency has acted within its statutory authority. While courts may still consider an agency's technical expertise, they are no longer legally bound to defer to its statutory interpretations.

2. Three Key Areas of Vulnerability for Federal Enforcement

With Chevron gone, several pillars of federal healthcare oversight have become vulnerable to direct legal challenge:

A. Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs)

Medicare Administrative Contractors (MACs) routinely use LCDs to restrict coverage for specific clinical procedures or drugs. In fraud investigations, prosecutors often cite a violation of an LCD as proof of billing fraud. Because LCDs are created by private contractors rather than Congress, their statutory authority is highly questionable. Under Loper Bright, defense counsel can challenge whether these restrictive contractor guidelines align with the actual Medicare statute, bypassing agency-level appeals.

B. The Stark Law and Anti-Kickback Statute (AKS) Regulations

The Stark Law and AKS are notoriously complex, relying heavily on HHS regulations to define safe harbors, fair market value, and commercial reasonableness. Previously, courts deferred to HHS's broad interpretations of "remuneration" or "volume or value of referrals." Now, defendants can challenge whether the agency's administrative exclusions and safe harbor definitions expand the statutes beyond what Congress originally enacted.

C. FDA Off-Label Enforcement and Clear Communication Rules

The FDA has historically restricted pharmaceutical manufacturers from promoting drugs for off-label uses, relying on broad interpretations of the Food, Drug, and Cosmetic Act (FDCA) concerning "intended use." Post-Chevron, courts will scrutinize whether FDA rules restricting clinical dissemination of peer-reviewed data exceed the agency's statutory mandate, particularly where free speech protections apply.

3. Strategic Implications for Active Fraud Defense

For attorneys defending physicians or executives facing civil False Claims Act (FCA) or criminal fraud allegations, the Loper Bright decision changes how defenses are constructed:

Challenging the Basis of the Indictment

Analyze whether the government's theory of fraud rests on a statutory violation or merely a violation of sub-regulatory guidance (such as CMS manual provisions, FAQs, or transmittals). If the underlying allegation is based on an agency's interpretation of a vague statute, move to dismiss the indictment on the grounds that the agency's interpretation exceeds its statutory limits.

The "Rule of Lenity" Reinforcement

In criminal cases, the rule of lenity requires courts to resolve ambiguities in criminal statutes in favor of the defendant. Under Chevron, agency interpretations often overrode this principle. Post-Chevron, the rule of lenity regained its full strength. If a billing rule is ambiguous, the court must resolve the ambiguity in favor of the clinical practitioner, not the prosecuting agency.

4. Future Outlook: Rebuilding Compliance Programs

Healthcare compliance programs must transition away from defensive, over-compliant models that treat sub-regulatory guidance as absolute law. Compliance officers should evaluate whether existing policies are structured around genuine statutory mandates or merely overly conservative interpretations of agency advisories. While adhering to OIG guidelines remains prudent to avoid audits, corporate entities now possess the judicial leverage to push back against unreasonable administrative overreach.